MGO One Seven’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-880
Closed -$265K – 1559
2026
Q2
$265K Buy
880
+100
+13% +$30.2K ﹤0.01% 1321
2026
Q1
$258K Sell
780
-53
-6% -$18K 0.01% 1218
2025
Q4
$331K Buy
833
+133
+19% +$58.9K 0.01% 1073
2025
Q3
$319K Buy
+700
New +$285K 0.01% 1003
2019
Q1
– Sell
-31
Closed -$2K – 461
2018
Q4
$2K Buy
+31
New +$2.38K ﹤0.01% 1538
2018
Q1
$2K Buy
16
+3
+23% +$387 ﹤0.01% 1516
2017
Q4
$2K Buy
+13
New +$1.63K ﹤0.01% 1490

Other funds holding ALNY

MGO One Seven's ALNY Position: Q3 2026 in Review

MGO One Seven sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2026, closing a stake of 880 shares — an estimated $265K sold.

MGO One Seven first reported a position in ALNY in Q4 2017 and held it in 7 quarters. The position peaked at $331K in Q4 2025. 722 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • MGO One Seven reported no remaining Alnylam Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • MGO One Seven sold 880 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $265K.
  • MGO One Seven first reported a position in Alnylam Pharmaceuticals in Q4 2017 and held it in 7 quarters.
  • MGO One Seven's Alnylam Pharmaceuticals position peaked at $331K in Q4 2025.
  • 722 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on MGO One Seven's 13F filing for Q3 2026, filed 28 Oct 2026.